Related Experiment Video
Updated: Jun 12, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success
1Division of Infectious Diseases, Department of Medicine, The Ottawa Hospital, G12-501 Smyth Road, Ottawa, Ontario K1H 8L6. ccooper@ottawahospital.on.ca
Abstract:
Currently, hepatitis C virus (HCV) antiviral therapy is characterized by long duration, a multitude of side effects, difficult administration and suboptimal success; clearly, alternatives are needed. Collectively, specifically targeted antiviral therapy for HCV (STAT-C) molecules achieve rapid viral suppression and very high rapid virological response rates, and improve sustained virological response rates. The attrition rate of agents within this class has been high due to various toxicities. Regardless, several STAT-C molecules are poised to become the standard of care for HCV treatment in the foreseeable future. Optimism must be tempered with concerns related to the rapid development of drug resistance with resulting HCV rebound. Strategies including induction dosing with interferon and ribavirin, use of combination high-potency STAT-C molecules and an intensive emphasis on adherence to HCV antiviral therapy will be critical to the success of this promising advance in HCV therapy.
Related Concept Videos
Hepatitis
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

